已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

A comparison of immediate release and delayed release cysteamine in 17 patients with nephropathic cystinosis

作者
Christina Esther van Stein,Sabrina Klank,Marianne Grüneberg,Chris Ottolenghi,Jürgen Grebe,Janine Reunert,Erik Harms,Thorsten Marquardt
出处
期刊:Orphanet Journal of Rare Diseases [BioMed Central]
卷期号:16 (1): 387-387 被引量:24
标识
DOI:10.1186/s13023-021-01991-2
摘要

BACKGROUND: Nephropathic cystinosis is a rare and severe metabolic disease leading to an accumulation of cystine in lysosomes which especially harms kidney function. A lifelong therapy with the aminothiol cysteamine can delay the development of end-stage renal disease and the necessity of kidney transplantation. The purpose of our study was to compare the effectiveness of immediate-release and delayed-release cysteamine on cystine and cysteamine levels as well as assessing the onset of adverse effects. METHODS: We retrospectively analysed cystine and cysteamine levels of 17 patients after a single dose of immediate-release cysteamine (Cystagon®, Mylan Pharmaceuticals, Canonsburg, PA and Recordati Pharma GmbH) as well as a single dose of delayed-release cysteamine (Procysbi®; Horizon Pharma USA and Chiesi Farmaceutici S.p.A., Parma, Italy) respectively. Data were collected during a period of three years in the context of optimizing the individual treatment regimens. The dose of DR-cysteamine was reduced to 70% of the equivalent dose of IR-cysteamine. The efficacy of both formulas in depleting white blood cells' cystine levels and their side effects were compared. RESULTS: Immediate (IR)- and delayed-release (DR) cysteamine effectively decreased intracellular cystine levels under the target value of 0.5 nmol cystine/mg protein, while fewer side effects occurred under DR-cysteamine. Mean maximum levels of cysteamine were reached after 60 min with IR-cysteamine and after 180 min with DR-cysteamine. CONCLUSION: A therapy with DR-cysteamine is as effective as IR-cysteamine while less side effects were reported. Our data show that DR-cysteamine should be dosed higher than 70% of the equivalent dose of IR-cysteamine in order to decrease cystine levels over an extended period of time. Moreover, our data suggest increasing the dosing scheme of Procysbi® to three times daily, to prevent a rapid decrease and achieve a steadier decline in cystine levels. Due to the more convenient dosing scheme, DR-cysteamine might ameliorate therapy adherence and improve patients' quality of life.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
羊咩咩发布了新的文献求助10
1秒前
111发布了新的文献求助10
1秒前
1秒前
Liona发布了新的文献求助10
2秒前
风吹麦浪的应助被chenming采纳,获得10
3秒前
3秒前
3秒前
4秒前
一颗蘑古力完成签到 ,获得积分10
4秒前
wang发布了新的文献求助10
4秒前
研友_VZG7GZ的应助被tingwaiwufengyu采纳,获得10
5秒前
顾矜的应助被529采纳,获得10
6秒前
6秒前
whz发布了新的文献求助10
7秒前
yzy完成签到,获得积分10
7秒前
Jasper的应助被爱笑的眼睛采纳,获得10
8秒前
奇迹完成签到,获得积分10
9秒前
9秒前
秃头泡泡发布了新的文献求助10
9秒前
Lucas的应助被栗子采纳,获得10
9秒前
钟zhong发布了新的文献求助10
9秒前
10秒前
顾矜的应助被卢敏明采纳,获得10
10秒前
10秒前
FFF完成签到,获得积分10
13秒前
Liona完成签到,获得积分10
13秒前
13秒前
Petrichor完成签到 ,获得积分10
13秒前
13秒前
Csy发布了新的文献求助20
14秒前
BH完成签到 ,获得积分10
14秒前
sci2025opt完成签到 ,获得积分10
15秒前
15秒前
bai完成签到 ,获得积分10
15秒前
15秒前
16秒前
16秒前
学必困完成签到 ,获得积分10
17秒前
BH关注了科研通微信公众号
17秒前
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179198
求助须知:如何正确求助?哪些是违规求助? 9569781
关于积分的说明 21806509
捐赠科研通 7774542
什么是DOI,文献DOI怎么找? 3433008
关于科研通互助平台的介绍 2556929
邀请新用户注册赠送积分活动 2478652